Harrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market

Simply Wall St.02-23

AdvertisementPharmaPack launch puts Harrow stock in focus Harrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613978903?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-02-23 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613978903","market":"nz","top_or_hot":-1,"title":"Harrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementPharmaPack launch puts Harrow stock in focus Harrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementPharmaPack launch puts Harrow stock in focus Harrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat","article_id":"2613978903","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613978903","pubTimestamp":1771846210,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"PharmaPack launch puts Harrow stock in focus\nHarrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic kits intended to replace off-label compounded products used around cataract surgery.\nSee our latest analysis for Harrow.\nThe PharmaPack announcement comes as Harrow’s short term share price momentum is strong, with a 1 month share price return of 16.93% and a 90 day share price return of 26.77%, set against a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","HROW":"Harrow Health Inc","BK4007":"制药"},"translate_title":"PharmaPack推出瞄准白内障手术市场，哈罗(HROW)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1.5},"content_text":"AdvertisementPharmaPack launch puts Harrow stock in focus Harrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic kits intended to replace off-label compounded products used around cataract surgery. See our latest analysis for Harrow. The PharmaPack announcement comes as Harrow’s short term share price momentum is strong, with a 1 month share price return of 16.93% and a 90 day share price return of 26.77%, set against a 1 year total shareholder return of 88.61% and a very large 5 year total shareholder return that is more than 6x. If PharmaPack has you thinking about where growth in healthcare could show up next, it may be worth checking out 27 healthcare AI stocks as a starting list of potential ideas. With Harrow trading at US$52, below an analyst price target of US$70.63 and an intrinsic value estimate suggesting a sizeable discount, the key question is whether there is still a buying opportunity available or if markets are already pricing in future growth. Most Popular Narrative: 26.4% Undervalued At a last close of $52, the most followed narrative pegs Harrow’s fair value at about $70.63, framing the current setup as a meaningful discount.  The analysts have a consensus price target of $60.1 for Harrow based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $76.0, and the most bearish reporting a price target of just $42.0.  Read the complete narrative. Curious what kind of revenue climb, margin shift, and profit multiple are baked into that fair value? The narrative leans on an ambitious earnings ramp and a future valuation that still sits below many peers. If you want to see exactly how those moving parts stack up year by year, the full story is worth a closer look. Result: Fair Value of $70.63 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, strong growth assumptions rely heavily on a few key drugs. Any slower uptake or pricing pressure could quickly challenge the current undervalued narrative. Find out about the key risks to this Harrow narrative. Next Steps If the mix of optimism and caution in this story feels familiar, you may want to move quickly and review the numbers yourself so you can decide whether the upside justifies the risks, starting with 3 key rewards. Looking for more investment ideas? If this has sharpened your focus on opportunities, do not stop at one stock. Broaden your watchlist and give yourself more options for your next move.  Prioritize resilience by scanning 85 resilient stocks with low risk scores that can help anchor your portfolio when sentiment turns. Hunt for quality at a discount with 53 high quality undervalued stocks that combine solid fundamentals with prices that may not reflect them. Spot potential early movers by reviewing a screener containing 23 high quality undiscovered gems before they attract wider attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Harrow might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613978903","isCrawlerRequest":true}